Our Leadership Team

Feng Tian, Ph.D

Chief Executive Officer
Feng Tian, Ph. D. is the Chief Executive Officer and President of Ambrx. He has held positions of increasing responsibility since the beginning of Ambrx. Previously, as Chief Scientific Officer Dr. Tian oversaw the company’s research and development. During his tenure at Ambrx, Dr. Tian has been instrumental in the establishment and improvement of Ambrx technology and product platforms. He played a key role in the establishment of the EuCODE technology platform (site-specific non-natural amino acid incorporation in eukaryotic cells). Additionally, he led multiple teams to establish Ambrx’s site-specific antibody drug conjugate (ADC) technology platform, the bi-specific antibody platform, and the “Life Switch” vaccine platform. Dr. Tian also initiated and established the Ambrx China Strategy. He played a central role in building China collaborations, and more recently, in Ambrx strategic transactions in 2015. Prior to joining Ambrx, Dr. Tian conducted his post-doctoral study at The Scripps Research Institute in Professor Peter G. Schultz’s group, where his work involved catalytic antibodies, non-natural amino acid incorporation, and biosensors. Dr. Tian received his Ph.D. in Chemistry from the University of Florida, with a dissertation in the field of Physical Organic Chemistry, under the supervision of Professor William R. Dolbier, Jr. He received his B. S. in Chemistry from Peking University.